Y
Y. Debie
Publications - 6
Citations - 69
Y. Debie is an academic researcher. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 1, co-authored 1 publications receiving 1 citations.
Papers
More filters
Journal ArticleDOI
Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment.
Marc Peeters,L. Verbruggen,Laure-Anne Teuwen,Greetje Vanhoutte,S. Vande Kerckhove,Bart Peeters,S. Raats,I. Van der Massen,S. De Keersmaecker,Y. Debie,Manon T. Huizing,Pieter Pannus,Kristof Y. Neven,Kevin K. Ariën,Kevin K. Ariën,Geert A. Martens,M. Van Den Bulcke,Ella Roelant,Isabelle Desombere,Sébastien Anguille,Maria E Goossens,Timon Vandamme,P. van Dam +22 more
TL;DR: In this paper, the BNT162b2 COVID-19 vaccine was administered 21 days apart to solid tumor patients receiving chemotherapy, immunotherapy, targeted or hormonal therapy and patients with a hematologic malignancy receiving rituximab or after allogeneic hematopoietic stem cell transplantation.
Journal ArticleDOI
Comparison of S1 antibody titers between BNT162b2 and ChAdOx1 COVID-19 vaccination in cancer patients
Peter A. van Dam,Y. Debie,Laure Anne Teuwen,Lisanne C Verbruggen,Greetje Vanhoutte,B. Peeters,Lieselot Croes,Christof Vulsteke,Sébastien Anguille,Timon Vandamme,Marc Peeters +10 more
TL;DR: In this paper , the authors reported differences in the humoral response 28 days post-booster dose in cancer patients vaccinated with either BNT162b2 (Pfizer-BioNTech, Puurs, Belgium) or ChAdOx1 (AstraZeneca, Seneffe, Belgium).
Journal ArticleDOI
Humoral and cellular immune responses against SARS-CoV-2 after third dose BNT162b2 following double-dose vaccination with BNT162b2 versus ChAdOx1 in cancer patients.
Y. Debie,Jonas Van Audenaerde,Timon Vandamme,Lieselot Croes,Laure Anne Teuwen,Lise Verbruggen,Greetje Vanhoutte,Elly Marcq,Lisa Verheggen,Debbie Le Blon,Bart Peeters,M. Goossens,Pieter Pannus,Kevin K. Ariën,Sébastien Anguille,Annelies Janssens,Hans Prenen,Evelien Smits,Christof Vulsteke,Eva Lion,Marc Peeters,Peter A. van Dam +21 more
TL;DR: In this paper , the authors compared a third dose of BNT162b2 after double-dose ChAdOx1 (heterologous) vaccination in cancer patients and found that a third heterologous dose was able to close the gap in antibody response.
Journal ArticleDOI
Boosting capacity of a fourth dose BNT162b2 in cancer patients
TL;DR: In this article , a third primary vaccination dose has been recommended for cancer patients to boost the humoural immune response against SARS-CoV-2 in order to improve the protection against COVID-19.
Journal ArticleDOI
Predictive model for BNT162b2 vaccine response in cancer patients based on blood cytokines and growth factors
Angelina Konnova,Fien H. R. De Winter,Lisanne C Verbruggen,An Hotterbeekx,M. Berkell,Laure Anne Teuwen,Greetje Vanhoutte,B. Peeters,Silke Raats,Isolde Van der Massen,Sven De Keersmaecker,Y. Debie,M. T. Huizing,Pieter Pannus,Kristof Y. Neven,K. K. ArieÌn,Geert A. Martens,Marc Van den Bulcke,Ella Roelant,Isabelle Desombere,Sébastien Anguille,Zwi N. Berneman,M. Goossens,Herman Goossens,Surbhi Malhotra-Kumar,E. Taconelli,Timon Vandamme,Marc Peeters,P. V. van Dam,Samir Kumar-Singh +29 more
TL;DR: In this article , the authors employed machine learning approaches to identify a biomarker signature based on blood cytokines, chemokines, and immune-and non-immune-related growth factors linked to vaccine immunogenicity in 199 cancer patients receiving the BNT162b2 vaccine.